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Abstract
To determine the effect of retinoic acid (RA) in neuroblastoma we treated RA sensitive neuroblastoma cell lines with 9-cis RA
or ATRA for 9 days, or for 5 days followed by absence of RA for another 4 days. Both isomers induced apoptosis and reduced
cell density as a result of cell differentiation and/or apoptosis. Flow cytometry revealed that 9-cis RA induced apoptosis
more effectively than ATRA. The expression profile of apoptosis and survival pathways was cell line specific and depended
on the isomer used.
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Introduction
During nervous system development several neuronal cells die
due to apoptosis, thus regulating the appropriate number of
neurons. The deregulation of this process and the subsequent
inability of tumour cells to enter apoptotic pathways may lead to
the appearance and progression of tumors, for which the
restoration of a normal apoptotic rate represents an important
antineoplastic therapy in tumor treatment. Retinoids exert
essential effects during embryonic development and differentiation
of several cell types [1,2] and have been studied as human cancer
therapeutics as they inhibit cell proliferation and induce cell
differentiation and apoptosis in several cancer types including
neuroblastoma [3,4]. Different RA isoforms have been used for
the treatment of neuroblastoma, either alone or in combination
with chemotherapy or radiation, exerting their anti-tumor effects
against neuroblastoma by the induction of apoptosis and/or
differentiation [5–10]. In vitro 9-cis RA and ATRA isomers are the
most common natural metabolites employed to induce apoptosis
and/or differentiation of neuroblastoma cell lines [11]. Interest-
ingly, the effect of RA has been reported to be dependent on the
cell line treated, being some of them sensitive and others resistant
to RA. For instance, it has been observed that SK-N-MC cells are
sensitive to ATRA induced apoptosis after short periods of time
(up to 72 h), while SK-N-FI cells are resistant to the same
treatment [8]. Furthermore, treatment of SH-SY5Y cells induces
their differentiation while suppression of the treatment favours
their entrance in the apoptotic pathway [12–15]. In contrast, SK-
N-AS cells do not show the morphological alterations typical of
differentiated cells and only show a slight inhibition of cell growth
after 8 days of exposure to RA [16], a reason for which this cell
line is usually employed as a RA resistant control.
Apoptosis may be induced either by extrinsic or intrinsic
pathways. The extrinsic or membrane receptor pathway is
initiated by the interaction of several membrane receptors such
as TNF Receptors, TRAIL Receptors, FAS or Death Receptors
(DR) with their ligands. After binding, the transformed receptor
induces both activator and effector caspases (caspases 8 and 10 and
caspases 3, 6 and 7, respectively). The intrinsic or mitochondrial
pathway is activated in response to different cell stimuli that lead to
the release of cytochrome C from the mitochondria, the formation
of the apoptosome complex and the activation of effector caspases
[17,18]. Besides the activation of the extrinsic pathway, the
interaction of TNF with its receptor can also initiate a phosphor-
ylation cascade that leads to NFKB1 transcription factor
activation, which would in turn induce transcription of inhibitor
of apoptosis proteins (IAPs) such as BIRC2, 3, 4, BCL2 or
BCL2L1, therefore favouring cell survival [19,20].
Here we report the effect on gene expression of apoptosis
related genes during the processes of cell apoptosis and differen-
tiation induced in neuroblastoma cell lines by treatment with
either 9-cis RA or ATRA. Both by TUNEL and qPCR array, 9-cis
RA revealed to be more efficient than ATRA inducing these
processes. Furthermore, the qPCR array revealed that RA affects
the expression of a different set of genes depending on the RA
isomer used and the treated cell line.
Materials and Methods
Cell Culture and Cell Lines
IMR-32, SH-SY5Y, SK-N-DZ, SK-N-Be(2) and SK-N-AS
neuroblastoma cell lines were obtained from ATCC (ATCC;
Manassas, VA). The cell lines were chosen because their different
RA sensitivity and genomic characteristics: IMR-32, SH-SY5Y,
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Figure 1. Time course analysis of induction of apoptosis in neuroblastoma cell cultures by Retinoic Acid. Percentage of dead cells in
IMR-32, SH-SY5Y, SK-N-DZ, SK-N-Be(2) and SK-N-AS cell cultures either untreated (control cells) or treated with (A) 9-cis RA or (B) ATRA for 9
consecutive days (RA(9)) or for 5 days followed by 4 days in the absence of RA (RA(5)) was determined by TUNEL after 1, 3, 5, 7 or 9 days of treatment.
Data are represented as mean 6 SEM (n= 3). Asterisks represent significant differences to the control (*, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0062771.g001
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SK-N-DZ, SK-N-Be(2) cells are RA sensitive, while SK-N-AS cells
were used as a negative control for RA treatment; SK-N-AS and
SH-SY5Y cells harbour a single copy of MYCN while IMR-32,
SK-N-DZ and SK-N-Be(2) cells show MYCN amplification at
different extents. Additionally, one allele of CASP8 is hyper-
methylated in IMR-32, SK-N-DZ, SK-N-Be(2) and SH-SY5Ycells
[21,22]. Each cell line was cultured at 37uC in an atmosphere
containing 5% CO2 and 96% relative humidity in DMEM
Glutamax (Invitrogen, Carlsbad, CA) culture medium supplemen-
ted with previously decomplemented fetal bovine serum (Invitro-
gen) at a final concentration of 10%, and with non essential amino
acids (Invitrogen) at a final concentration of 5%. Plasmocin
(Invivogen, San Diego, CA) was used as antibiotic at a final
concentration of 5 mg/ml. Cells were cultured in 75 cm2 flasks
(Nunc, Roskilde, Denmark) and medium was changed every 48 h.
RA Treatment
For retinoic acid treatment, cells were seeded in 75 cm2 flasks at
1.5 million cells/flask final concentration. After 24 h cells were
washed and medium replaced by fresh medium including either
the corresponding isomer of RA, 9-cis RA (Sigma, St. Louis, MO)
or ATRA (Sigma) at a final concentration of 1 mM, or the vehicle
(70% ethanol in the case of 9-cis RA, and DMSO in the case of
ATRA) at a final concentration of 0.1%. Cells were treated for 9
days, or for 5 days followed by 4 days in which cells were
maintained in absence of RA. Cell medium was changed every
48 h. At every change, apoptotic cells were recovered from old
medium by centrifugation (5 min, 1,500 rpm) and re-added to the
culture with the new medium.
Apoptosis Detection
Apoptosis was determined by flow cytometry using the
Apodirect Kit (BD Biosciences, San Diego, CA), which is based
on the TUNEL technique under the conditions described by the
manufacturer. Briefly, as neuroblastoma cells need at least 7 days
to differentiate in vitro [23], cells were treated as described above
either for 9 days or for 5 days followed by 4 days in absence of RA.
Apoptosis was measured at days 1, 3, 5, 7 and 9. With this purpose
cells were trypsinized, fixed in 1% paraformaldehide, stained with
propidium iodide and FITC and analyzed in an EPICS-XL-4CLR
flow cytometer (Beckman Coulter, Miami, Florida, USA). Cells
were excited with an argon laser emitting at 488 nm and
propidium iodide was detected using 620 nm band pass filter.
RET and MYCN Expression Detection
To determine whether RA induced cell differentiation, RET
and MYCN expression levels were measured by quantitative PCR
(qPCR). Cells were treated as described above for 9 or 5 days. At
days 1, 3, 5, 7 and 9 cells were trypsinized and collected by
centrifugation. RNA was extracted from a maximum of 5 million
cells per sample using the RNeasy extraction kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. After
RNA extraction, 1 mg of total RNA was retrotranscribed using the
SuperScriptTM Reverse Transcriptase (Invitrogen) in the condi-
tions described by the manufacturer.
RET, MYCN and GAPDH primers were designed using the
‘‘Beacon Designer 3.010 software. Primer sequences were:
GAPDH-F: 59GGAGTCCACTGGCGTCTTC39
GAPDH-R: 59ATCTTGAGGCTGTTGTCATACTTC39
RET-F: 59CATGGGCGACCTCATCTC3’
RET-R: 59GAAATCCGAAATCTTCATCTTCC39
MYCN-F: 59ACCAGCGGCGGCGACCAC 39
MYCN-R: 59GTTCTTGGGACGCACAGTGATGG 39
Each amplicon was cloned into a pGEM T vector to create
pQRTGAPDH, pQRTRET and pQRTMYCN plasmids. These
plasmids were transformed in JM109 High Efficiency Competent
Cells (Promega, Madison, WI). The efficiency of each primer set
was calculated by making quantitative PCRs using serial dilutions
(2–0.002 ng of DNA) of each plasmid as template.
To study the expression of the selected genes in the cell lines
treated with RA we performed quantitative PCRs. The expression
of RET, MYCN and GAPDH was measured using the Brilliant
SYBR Green QPCR Master Mix (Stratagene, La Jolla, CA).
Briefly, the master mix was mixed with the primers at a final
concentration of 5 mM, and 14.5 ml of the mix were added to each
well, adding 2 ng of cDNA diluted in 10.5 ml of water to each well.
The qPCRs were performed in a chromo 4 thermal cycler (MJ
Research, Bio-Rad, Hercules, CA) in the following conditions: one
cycle of 109 at 95uC, to activate the HotStart DNA polymerase,
followed by 40 cycles of denaturation at 95uC for 30 s and
annealing and extension at 60uC for 30 s. SYBR Green
fluorescence was measured at every cycle.
qPCR Arrays
Cells were treated with RA as previously described, and
trypsinized after 5 days of treatment, collected by centrifugation,
and RNA extracted as described above. After RNA extraction,
1 mg of total RNA was retrotranscribed to cDNA using the RT2
First Strand Kit (Superarray, Hilden, Germany) as described by
the manufacturer. Real time PCR was performed using the RT2
Profiler PCR array system focused on the expression of cell
survival and apoptotic genes (Ref.: PAHS-012, Superarray,
Hilden, Germany). The RT2 qPCR Master Mix (Superarray)
was prepared in the conditions described by the manufacturer.
Briefly, a master mix containing 1 mg of cDNA was prepared, and
25 ml of the mix were added to each well of the PCR array. The
qPCR was performed in a Chromo 4 thermal cycler (MJ
Research, Bio-Rad, Hercules, CA) in the following conditions:
one cycle of 10 min at 95uC, to activate the HotStart DNA
polymerase, followed by 40 cycles of denaturation at 95uC for
15 s, annealing at 55uC for 30 s, and extension at 72uC for 30 s.
SYBR Green fluorescence was measured in every cycle.
Statistical Analysis
We performed at least four duplicated independent experiments
for the TUNEL assay and three independent experiments for the
qPCRs, which were analyzed using the DDC(t) method. Distribu-
tion of the samples was analyzed by using the Shapiro Wilks and
Kolmogorof-Smirnov tests and for statistical significance of the
gene expression variation the student t test taking p,0.05 as the
criterion for significance. Data were analyzed using the SPSS 15.0
program for Windows. Results are expressed as mean 6 SEM.
Results
9-cis RA is a More Efficient Apoptosis Inducer than ATRA
To compare the ability of different RA isomers to induce
apoptosis of neuroblastoma cells, we measured the apoptotic status
of the cells in IMR-32, SH-SY5Y, SK-N-DZ and SK-N-Be(2) cell
cultures treated with either 1 mM 9-cis or ATRA for 9 days or for 5
days as described above. The RA resistant SK-N-AS cell line was
used as a negative control. As shown in Figure 1A, treatment with
9-cis RA induced a significant increase in the percentage of
apoptotic cells in all the cultures but SK-N-AS. The increase in the
apoptotic level was observed from the 3rd day in IMR-32 cell
cultures, from the 5th day in SK-N-DZ and SK-N-Be(2) cell
cultures and from the 7th day in SH-SY5Y cell cultures. Moreover,
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while the percentage of apoptotic cells sustained over treatment,
suppression of 9-cis RA on the 5th day reduced the percentage of
apoptotic cells in IMR-32 and SK-N-DZ cultures but not in SH-
SY5Y and SK-N-Be(2) cultures, thus indicating that the presence
Figure 2. Morphological alterations induced in neuroblastoma cell lines treated with retinoic acid. Control cells (A, D, G, J and M) and
cells treated with 9-cis RA (B, E, H, K and N) or ATRA (C, F, I, L and O) are shown. The images shown were taken at different time points: A: Day 1; B: Day
9; C: Day 5; D: Day 5; E: Day 3; F: Day 9; G: Day 1; H: Day 3; I: Day 5; J: Day 9; K: Day 9; L: Day 9; M: Day 1; N: Day 7; O: Day 5; All images were taken at
100X.
doi:10.1371/journal.pone.0062771.g002
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of RA is necessary for the maintenance of apoptosis in IMR-32
and SK-N-DZ cells. In the case of treatment with ATRA, while
treatment did not induce a significant increase of apoptosis in SH-
SY5Y cell cultures, induction of apoptosis started on the 3rd day in
SK-N-DZ cell cultures, on the 5th day in SK-N-Be(2) cell cultures
and on the 7th day in IMR-32 cell cultures (Figure 1B). The
percentage of apoptotic cells persisted after suppression of the
treatment in the four cell lines.
Previous works have described that both 9-cis and all trans
retinoic acid isomers induce differentiation in neuroblastoma cell
lines [24]. To determine whether RA effectively induced
differentiation apart from apoptosis in our experimental system,
we analyzed the morphological alterations of the cells observed
during the treatment. As shown in Figure 2, while no morpho-
logical changes were observed in the RA resistant SK-N-AS cell
cultures, exposure to RA of IMR-32, SH-SY5Y, SK-N-DZ and
SK-N-Be(2) cells induced an augmentation in the number and
length of the neuritic extensions, which can even connect with the
extensions of neighbour cells. These alterations in cell morphology
are typical of cells undergoing differentiation and were more
evident in the cells treated with 9-cis RA than in those treated with
ATRA. Furthermore, as a result of the treatment total cell number
in the cultures decreased, which correlates with both cell
differentiation and the apoptosis described above.
To confirm differentiation of the RA sensitive cell lines, the
variation on the expression levels of the oncogenes RET [25–27]
and MYCN [28], relative to GAPDH, were determined by qPCR
by the DDCt method [29]. Figure 3A and B show that both 9-cis
RA and ATRA led to a significant increase in RET expression in
every RA sensitive cell line, thus indicating the capability of RA to
induce cell differentiation. Nevertheless, reached expression level
was dependent on the treated cell line and the isomer used.
Furthermore, we observed that the presence of RA is essential to
maintain RET expression level, as the suppression of the treatment
on the 5th day led to a decrease in the expression of RET, reducing
it to the same level than in control cells.
MYCN expression levels (Figure 3C and D) were measured the
9th day of treatment, and both 9-cis RA and ATRA inhibited its
expression in SH-SY5Y, SK-N-DZ and SK-N-Be(2) cells, but not
in the RA resistant SK-N-AS cell cultures neither in the RA
sensitive IMR-32 cells. Since the IMR-32 cell line harbours 2
different phenotypes, one of undifferentiated cells and the other of
proliferative cells that we have not separated, this might be and
explanation for the lack of MYCN down-regulation by RA in this
cell line. Additionally, suppression of either 9-cis RA or ATRA on
day 5 in SH-SY5Y, SK-N-DZ and SK-N-Be(2) cells lead to an
increase in MYCN expression on day 9, that shows up at different
extent on each cell line, as compared with those cells where
treatment was maintained, indicating that the presence of RA is
necessary to inhibit MYCN expression. These results suggest that
the differences observed in the modification of MYCN expression
among cell lines might in part be due to the different MYCN copy
number that possesses each one and reflect the different capability
of RA to induce cell differentiation depending on the cell type.
All together these results show that RA is able to induce
apoptosis and differentiation in neuroblastoma cell cultures.
Moreover, since higher percentages of apoptotic cells were
detected in 9-cis RA versus ATRA treated cell cultures (p,0.05
at day 5 in SK-N-DZ and IMR32 cells; p,0.05 at day 7 and day 9
in SHSY5Y and SK-N-DZ cells treated continuously; p,0.05 at
day 7 and day 9 in SHSY5Y, SK-N-DZ and SK-N-Be(2) cells
treated until day 5), results also suggest that 9-cis RA is a more
efficient apoptosis inducer than ATRA in neuroblastoma cells.
The Treatment of Neuroblastoma Cell Lines with 9-cis RA
Alters the Expression of a Heterogeneous Group of
Genes
Since in most cases the level of apoptosis was significantly
increased after 5 days of treatment with RA, we next decided to
analyze the expression level of apoptosis related genes at that
moment. Thus, we treated the different cell lines with 9-cis RA as
previously described and, after treatment, we analyzed by qPCR
(RT2 Profiler PCR array PAHS-012, Superarray) the expression
level of 84 genes related to apoptotic and survival pathways.
Obtained results are shown in Table 1. Only those genes whose
expression augmented more than 2-fold or those whose expression
was reduced to less than their half are displayed. Results show that
the treatment altered the expression level of 20 genes in IMR-32
cells, where expression of 16 genes (BCL2L11, BIRC3, BIRC8,
CARD6, CASP1, CASP5, CASP7, CASP10, CD40LG, CD70,
FASLG, LTA, LTBR, TNFRSF10A, TNFRSF11B and
TNFRSF21) was increased and expression of 4 genes (APAF1,
BCL10, CASP6 and HRK) was inhibited. Thirteen genes were
modified in SH-SY5Y cells, where 12 genes (BIK, BIRC3,
CARD6, CASP1, CASP4, CD70, PYCARD, RIPK2, TNFRSF9,
TNFRSF10A, TNFRSF10B and TNFSF10) were overexpressed
and one gene (CD40) was downregulated. Thirteen genes were
modified in SK-N-DZ cells, 11 of which (BCL2A1, BIRC3,
CASP1, CASP5, CASP8, CASP10. CASP14, NOL3, TNFRSF9,
TNFRSF11B and TNFSF10) increased their expression, while 2
(HRK and TNF) decreased it. Finally, expression of 9 genes was
altered in the SK-N-Be(2) cells, 6 of which (BIK, LTBR,
PYCARD, TNFRSF1A, TNFRSF10B, TNFRSF25) were over-
expressed and 3 of which (BCL2L10, CD27 and TP73) were
downregulated. Although the response of the 4 cell lines to the
treatment with 9-cis RA was similar, i. e. induction of apoptosis,
these results show that apoptosis related genes respond to 9-cis RA
treatment in a very heterogeneous and cell line dependent
manner.
ATRA Alters Both Apoptotic and Survival Pathways in
Neuroblastoma Cell Lines
To study the effect of ATRA on the expression level of apoptosis
related genes in neuroblastoma cell lines, we treated IMR-32, SH-
SY5Y, SK-N-DZ and SK-N-Be(2) cell cultures as described above
for 9-cis RA. After treatment gene expression levels were analyzed
by qPCR. Obtained results are shown in Table 2. As shown, 7
genes were modified in IMR-32 cells, where 2 genes were
upregulated (CIDEA and TNFRSF9) and 5 genes (APAF1,
CD30L, TNFRSF1A, TNFRSF25 and TP53) downregulated.
Eight genes were altered in SH-SY5Y cells; in this case the
Figure 3. Time course analysis of the differentiation process induced in neuroblastoma cell cultures by Retinoic Acid. Expression
levels of the oncogenes RET and MYCN were measured in IMR-32, SH-SY5Y, SK-N-DZ, SK-N-Be(2) and SK-N-AS cell cultures either untreated (control
cells) or treated with 9-cis RA or ATRA for 9 consecutive days (RA(9)), or treated for 5 days followed by 4 days in the absence of RA (RA(5)). Expression
levels were measured by qPCR as described in Materials and Methods and are shown relative to GAPDH. RET levels in cells either untreated (control)
or treated with (A) 9-cis RA or (B) ATRA were determined at days 1, 3, 5, 7 and 9. MYCN levels in cells either untreated (control) or treated with (C) 9-cis
RA or (D) ATRA were measured at day 9. Data are represented as mean 6 SEM (n= 3). Asterisks represent significant differences to the control (*,
p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0062771.g003
Retinoic Acid and Gene Expression in Neuroblastoma
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e62771
expression of 6 genes was increased (BIRC3, CASP1, CD70.
CIDEA, TNFRSF10B and TNFSF10) and 2 genes were down-
regulated (APAF1 and BFAR). Expression of 8 genes was modified
in SK-N-DZ cells, 7 of which were upregulated (CASP1, CASP5,
CASP8, CASP10, CD40LG, TNFRSF11B and TNFSF10) and
one gene was downregulated (HRK). Finally, 5 genes were
modified in SK-N-Be(2) cells, 4 of which were upregulated
(CASP3, CASP10, LTBR and TNFRSF25) and one gene
downregulated (TP73). As described above for 9-cis RA, these
results suggest that the effect of ATRA is specific of the cell line
treated, since expression of various genes is differently altered in
each particular cell line. Moreover, final response to the treatment
with ATRA also seems to be dependent on the cell line treated, as
ATRA did not induce a significant apoptotic increase in SH-SY5Y
cells, while it did it in the rest of the lines: in IMR-32 cells ATRA
induced a significant increase of apoptosis, but not comparable to
the one observed in SK-N-DZ and SK-N-Be(2) cells, in which
apoptosis levels increased among the 3rd and 5th day of treatment
and sustained until the end of the treatment (Figure 1).
Discussion
In this work we have analyzed the effect of the treatment of
neuroblastoma cell lines with 9-cis RA or ATRA in cell apoptosis
and differentiation. The overexpression of RET and the inhibition
Table 1. Genes of the apoptotic pathway overexpressed at
least two times, or downregulated by 50%, after treatment of
neuroblastoma cell lines with 9-cis RA.
Upregulated Genes IMR32 SH-SY5Y SK-N-DZ SK-N-Be(2)
BCL2A1 – – 2,077* –
BIK – 2,93** – 3,105*
BIM 3,202* – – –
CARD6 5,546** 5,633* – –
CASP1 2,704* 3,567** 3,251* –
CASP10 2,922* – 3,945* –
CASP14 – – 2,151** –
CASP4 – 1,935* – –
CASP5 7,708* – 4,193* –
CASP7 2,62* – – –
CASP8 – – 4,889* –
CD137 – – 10,693* –
CD40LG 7,24* – – –
CD70 2,061* 5,818** – –
cIAP2 2,15** 5,766** 4,565* –
DR3 – – – 4,492*
DR6 2,321** – – –
FASLG 3,239* – – –
ILP2 5,015* – – –
NOL3 – – 2,056* –
PYCARD – 2,873* – 2,23*
RIPK2 – 3,226* – –
TNF-RI – – – 4,854*
TNF-RIII 3,102* – – 5,469**
TNFRSF11B 2,414* – 5,106* –
TNFRSF9 – 5,164* – –
TNFb 3,634** – – –
TRAIL – 26,057** 5,714** –
TRAIL-RI 4,147* 2,731* – –
TRAIL-RII – 2,756** – 3,199*
Downregulated genes IMR32 SH-SY5Y SK-N-DZ SK-N-Be(2)
APAF1 0,466* – – –
BCL10 0,424** – – –
BCL2L10 – – – 0,408*
CASP6 0,508* – – –
CD27 – – – 0,455*
CD40 – 0,51* – –
HRK 0,48* – 0,135** –
TNF – – 0,346* –
TP73 – – – 0,394*
Genes significantly upregulated or downregulated more than 2-fold are
represented. Asterisks indicate significant differences among control and
treated cells (*, p,0.05; **, p,0.01). Lines (–) indicate that these genes were
neither overexpressed at least two times, nor downregulated by 50% after the
treatment.
doi:10.1371/journal.pone.0062771.t001
Table 2. Genes of the apoptotic pathway overexpressed at
least two times, or downregulated by 50%, after treatment of
neuroblastoma cell lines with ATRA.
Upregulated genes IMR32 SH-SY5Y SK-N-DZ SK-N-Be(2)
CASP1 – 2,024** 3,464* –
CASP10 – – 3,905* 2,609*
CASP3 – – – 1,922*
CASP5 – – 2,202* –
CASP8 – – 3,700* –
CD137 3,523* – – –
CD40LG – – 3,302* –
CD70 – 5,257** – –
cIAP2 – 4,281** – –
CIDEA 1,938* 2,007* – –
DR3 – – – 2,432*
TNF-RIII – – – 1,951*
TNFRSF11B – – 6,467* –
TRAIL – 2,952* 5,816** –
TRAIL-RII – 2,003* – –
Downregulated genes IMR32 SH-SY5Y SK-N-DZ SK-N-Be(2)
APAF1 0,593* 0,53* – –
BFAR – 0,572* – –
CD30L 0,238* – – –
DR3 0,507* – – –
HRK – – 0,126* –
TNF-RI 0,288* – – –
TP53 0,643** – – –
TP73 – – – 0,341*
Genes significantly upregulated or downregulated more than 2-fold are
represented. Asterisks indicate significant differences among control and
treated cells (*, p,0.05; **, p,0.01). Lines (–) indicate that these genes were
neither overexpressed at least two times, nor downregulated by 50% after the
treatment.
doi:10.1371/journal.pone.0062771.t002
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of MYCN oncogenes as markers of cell differentiation [25–27]
[28] and the effect of RA as an inducer of cell differentiation in
neuroblastoma cell cultures [24] have been widely described.
Accordingly, we have found that despite some specific differences
in the response to 9-cis and ATRA among cell lines, both RA
isomers induce the morphological alterations typical of cell
differentiation and increase RET expression in every one of the
RA sensitive tested cell lines (Figures 2 and 3), while MYCN
expression was inhibited in three of the four cell lines (Figure 3).
Additionally, we have also found that both RA isomers are able to
increase the percentage of apoptotic cells in the cultures. However,
the apoptotic response of the cells was quite heterogeneous. Thus,
apoptosis induction by 9-cis RA showed up rapidly in IMR-32,
SK-N-DZ and SK-N-Be(2) cells, where it began between the 3rd
and the 5th day of treatment, while SH-SY5Y cells were more
resistant (Figure 1A). Interestingly, other groups have reported
induction of apoptosis by 9-cis RA in SH-SY5Y cells only after
suppression of the treatment [12,14]. In our study we also
observed some increase in the percentage of apoptotic cells when
the treatment was suppressed, although this increase was not
comparable to the one observed when cells were treated
continuously for a long length time. However, apoptosis level
kept high in SK-N-Be(2) cells and decreased in IMR-32 and SK-
N-DZ cell cultures when treatment was suppressed. These results
suggest either that SH-SY5Y and SK-N-Be(2) cells are more
sensitive to 9-cis RA than SK-N-DZ and IMR-32 cells, or that
although apoptotic pathways are activated in the four cell lines, 9-
cis RA would also induce the activation of survival pathways in
SK-N-DZ and IMR-32 cells. On the other hand, when cells were
treated with ATRA induction of apoptosis began after 3 and 5
days of treatment in SK-N-DZ and SK-N-Be(2) cell cultures, and
only after 7 days in IMR-32 cell cultures (Figure 1B). However,
ATRA treatment did not induce a significant increase of apoptosis
in SH-SY5Y cell cultures. Furthermore, the percentage of
apoptotic cells in the cultures maintained steady after the
suppression of the treatment in the four cell lines. These results
may indicate that SK-N-DZ and SK-N-Be(2) cell lines respond
equally to both isomers and suggest that the same apoptotic
pathways are activated in these lines after the treatment with any
of the RA isomers. Results also suggest that ATRA is a less
efficient apoptosis inductor than 9-cis RA in IMR-32 and SH-
SY5Y cells.
Analysis of the effect of RA on the expression profile of genes
related to apoptosis and cell survival showed that modified genes
had either proapoptotic or antiapoptotic actions. According to the
modification (up or down-regulation) and function of each gene
(pro or antiapoptotic) we divided them into two groups: those
whose modification would induce apoptosis and those that would
inhibit apoptosis. The first group was formed by proapoptotic
genes whose expression was increased and by antiapoptotic genes
whose expression was decreased after the treatment, while the
second group was formed by antiapoptotic genes whose expression
was increased and by proapoptotic genes whose expression was
decreased after the treatment. According to this division we
analyzed the relationship among the apoptosis level observed upon
RA treatment (Figure 1) and the pro and antiapoptotic genes
modified at each cell line by either of the RA isomers (Figure 4).
Analysis suggests that treatment with either 9-cis RA or ATRA
induces apoptosis by the activation of the extrinsic and p53
pathways in SH-SY5Y and SK-N-Be(2) cells (Figures 5 and 6).
However, only 9-cis RA would be able to activate these pathways
in IMR-32 cells (Figure 7). Activation of the extrinsic pathway is
supported by the fact that after treatment expression of TNF10
and its receptors TNFRSF10A or TNFRSF10B in SH-SY5Y cells,
expression of LTBR, TNFRSF1A, TNFRSF10B or TNFRSF25 in
SK-N-Be(2) cells and expression of TNFRSF10A, LTA and
FASLG in IMR-32 are augmented. Furthermore, the elevation of
Figure 4. Edwards-Venn diagrams of genes of the apoptotic
pathway whose expression was altered in neuroblastoma cell
lines after RA treatment. Genes overexpresed at least 2 times (up
arrows) or downregulated by 50% (down arrows) after 5 days of
treatment either with 9-cis RA or ATRA. (A) IMR-32, (B) SH-SY5Y, (C) SK-
N-DZ and (D) SK-N-Be(2). The line represents the division among the
modified genes that would induce and inhibit apoptosis.
doi:10.1371/journal.pone.0062771.g004
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Figure 5. Effect of RA treatment over apoptotic and cell survival pathways in SH-SY5Y RA sensitive cell line. In green colour are
represented those genes whose expression has been augmented as a result of 9-cis RA (A) or ATRA (B) treatment, while in red are shown those whose
expression has been decreased. Green arrows indicate the pathways that will be activated while red arrows indicate the pathways that will be
inhibited as a consequence of the modifications of the genes that take part in these pathways. CM: Cell Membrane; Cyt: Cytoplasm; Mit:
Mitochondrion; Nuc: Nucleus; P: Phosphorous.
doi:10.1371/journal.pone.0062771.g005
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Figure 6. Effect of RA treatment over apoptotic and cell survival pathways in SK-N-Be(2) RA sensitive cell line. In green colour are
represented those genes whose expression has been augmented as a result of 9-cis RA (A) or ATRA (B) treatment, while in red are shown those whose
expression has been decreased. Green arrows indicate the pathways that will be activated while red arrows indicate the pathways that will be
inhibited as a consequence of the modifications of the genes that take part in these pathways. CM: Cell Membrane; Cyt: Cytoplasm; Mit:
Mitochondrion; Nuc: Nucleus; P: Phosphorous.
doi:10.1371/journal.pone.0062771.g006
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Figure 7. Effect of RA treatment over apoptotic and cell survival pathways in IMR-32 RA sensitive cell line. In green colour are
represented those genes whose expression has been augmented as a result of 9-cis RA (A) or ATRA (B) treatment, while in red are shown those whose
expression has been decreased. Green arrows indicate the pathways that will be activated while red arrows indicate the pathways that will be
inhibited as a consequence of the modifications of the genes that take part in these pathways. CM: Cell Membrane; Cyt: Cytoplasm; Mit:
Mitochondrion; Nuc: Nucleus; P: Phosphorous.
doi:10.1371/journal.pone.0062771.g007
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Figure 8. Effect of RA treatment over apoptotic and cell survival pathways in SK-N-DZ RA sensitive cell line. In green colour are
represented those genes whose expression has been augmented as a result of 9-cis RA (A) or ATRA (B) treatment, while in red are shown those whose
expression has been decreased. Green arrows indicate the pathways that will be activated while red arrows indicate the pathways that will be
inhibited as a consequence of the modifications of the genes that take part in these pathways. CM: Cell Membrane; Cyt: Cytoplasm; Mit:
Mitochondrion; Nuc: Nucleus; P: Phosphorous.
doi:10.1371/journal.pone.0062771.g008
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Figure 9. Overlapping pattern of genes modified by RA treatment of neuroblastoma cell lines. Edwards-Venn diagrams showing the
genes overexpressed at least 2 times (up arrows) or downregulated by 50% (down arrows) after 5 days of RA treatment of the corresponding cell line.
(A) Genes modified by 9-cis RA. (B) Genes modified by ATRA.
doi:10.1371/journal.pone.0062771.g009
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the levels of the membrane receptors and their ligands in these cell
lines is followed by the overexpression of CASP1, CASP3, CASP5,
CASP7, CASP10 or PYCARD, which will favour the entrance of
the cells into the apoptotic process. In SH-SY5Y cells treated with
ATRA, downregulation of the caspase inhibitor BFAR will also
contribute to the apoptotic process. Activation of the p53 pathway
is supported by induction of BIK expression in SH-SY5Y and SK-
N-Be(2) cells and of BCL2L11 expression in IMR-32 cells, since
BIK and BCL2L11 are BCL2 interacting factors that block its
antiapoptotic activity hence leading to the activation of p53
dependent genes [30]. However, activation of the apoptotic
intrinsic pathway is less probable since treatment of IMR-32 and
SH-SY5Y cells with 9-cis RA leads to an increase of BIRC3 and
BIRC8 (an inhibitor of APAF1, BAX and Caspase 9 [31,32]) and
to a decrease of APAF1 and BCL10 (an activator of Caspase 9
[33]), thus suggesting a lesser formation of the apoptosome and
a blockade of the pathway.
It has to be noticed that the IMR-32 cell line consists of 2
phenotypes: one phenotype is formed by a pool of undifferentiated
cells, and the other by proliferative cells able to become adherent
epithelial like cells [34]. Taking into account that in this work we
have not separated the two phenotypes and that during the
treatment we observed by microscopy that the undifferentiated
cells entered apoptosis and the proliferative cells differentiated to
adherent cells (Figures 2A, B and C), the analysis of the
modifications on the expression profile of genes related to
apoptosis and cell survival suggests that the treatment of IMR-
32 with 9-cis RA would favour cell survival and differentiation in
the proliferative cells through the activation of signalling pathways
such as those regulated by NFKB1, p38, MAPK and/or JNK. The
activation of these pathways in the undifferentiated cells seems less
probable. Several facts support this idea. First, the expression level
of CARD6 is increased as a consequence of the treatment, and it
has been described that the interaction of CARD6 with NOD1
and RIPK2 suppresses the activation of NFKB1 induced by these
two proteins and so its survival effect [35]. Second, BCL10 levels,
a protein that regulates the NFKB1 signalling pathway [36,37],
decreased as a consequence of the treatment. Third, levels of
CD40LG increased as a consequence of the treatment, and since it
has been shown that CD40 activation causes TRAF2 degradation
in B cells [38] this result suggests that treatment leads to a decrease
in TRAF2 activity and so to a blockade in the NFKB1 and MAPK
signalling pathways and the inhibition of their cell survival effects;
the increase in the expression of BIRC3, an antiapoptotic protein
capable of both binding TRAF2 and inhibit caspase activities
[33,39] could be the consequence of a compensatory mechanism
that would try to maintain the function of these pathways; anyway,
it has to be taken into account that the capability of BIRC3 to
inhibit apoptosis is very weak and that the main reason of its
binding to TRAF2 seems to be to mediate or modulate receptor
signalling [31]. Fourth, caspase 1 levels increased as a consequence
of the treatment but as previously commented, the activating effect
of caspase 1 over RIPK2 [32] is probably counteracted by the
elevation of CARD6. Overexpression of CARD6 and BIRC3 was
also observed in SH-SY5Y cells treated with 9-cis RA, making the
induction of cell survival by the activation of NFKB1 improbable
in this cell line. However, treatment with ATRA induces
expression of BIRC3 in SH-SY5Y cultures but does not modify
CARD6 expression levels, thus suggesting the phosphorilation of
IKK and NFKB1 and the activation of the survival pathway. The
activation of this pathway might be the reason for not detecting
a significant increase of apoptosis during the first days of
treatment. Besides the activation of the extrinsic pathway, CIDEA
overexpression might also contribute to the induction of apoptosis
detected after 5 days.
The reduction in the expression levels of TNFRSF1A,
TNFRSF25, TP53 and APAF1 is the main result observed after
the treatment of IMR-32 cells with ATRA (Figure 7). Since the
reduction of APAF1 decreases the levels of the apoptosome and
thus the induction of apoptosis by the intrinsic pathway, and
TNFRSF1A and TNFRSF25 are receptors that take part in the
activity of both the extrinsic and NFKB1 pathways [40,41], this
result suggests the inhibition of those pathways and the existence of
a balance among the processes of apoptosis and cell survival.
CIDEA is the only proapoptotic gene that we found overexpressed
in IMR-32 cells after ATRA treatment. This result, that contrasts
with the reduction in its levels observed after the treatment of
mature 3T3-L1 adipocites with ATRA [42,43], is significant as it
allows to explain the increase of apoptosis detected from the 7th
day on, if we suppose that it is in this moment when the levels of
CIDEA are superior to the levels of its inhibitor ICAD.
In contrast with the previous observations, analysis of the
modifications induced by treatment with RA on the expression
profile of genes related to the processes of apoptosis and cell
survival in the SK-N-DZ cells suggests that induction of apoptosis
by RA in this cell line is a consequence of its action over caspases
1, 5, 8 and 10, whose expression levels were incremented
(Figure 8). Moreover, the decrease in the expression level of
TNF, and the overexpression of NOL3, an inhibitor of FAS and
FADD after 9-cis RA treatment, suggest that it is not very likely
that the increase of apoptosis is due to the activation of the
extrinsic pathway at the level of membrane receptors. Similarly,
the overexpressions of NOL3, BCL2A1 and BIRC3, together with
the decrease in HRK levels, seem to discard the activation of the
intrinsic pathway. Furthermore, the overexpression of caspases 1
and 5 could lead to the phosphorilation of IKK with the
subsequent activation of NFKB1, which would explain the decline
in the apoptosis induction observed in this cell line after 5 days of
treatment.
The overlap among genes whose expression level was modified
in a particular cell line after treatment with either of the RA
isomers is shown in Figure 4. Only the APAF1 gene was modified
by both RA isomers in IMR-32 cells (Figure 4A), while BIRC3,
CASP1, TNFRSF10B, TNFSF7 and TNFSF10 were modified in
SH-SY5Y cells (Figure 4B), CASP1, CASP5, CASP8, CASP10,
HRK, TNFRSF11B and TNFSF10 were modified in SK-N-DZ
cells (Figure 4C), and LTBR, TNFRSF25 and TP73 in SK-N-
Be(2) cells (Figure 4D). The overlap among genes modified in the
different cell lines by each treatment is shown in Figure 9: no gene
was modified in every cell line after treatment with either of the
isomers. On the other hand, treatment with 9-cis RA but not with
ATRA induced overexpression of BIRC3 and CASP1 in IMR-32,
SH-SY5Y and SK-N-DZ cell lines. Finally, several genes were
modified in only one or two of the 4 cell lines after treatments.
Taking together, these results suggest that both 9-cis RA and
ATRA are able to induce differentiation in neuroblastoma cell
lines, while they differ in their capability to induce apoptosis.
Furthermore, analysis of the expression profile of apoptosis and
survival pathways suggests that the effect of the treatment is cell
line specific and depends on the isomer used, being the effect of
the 9-cis isomer stronger than that of the all-trans.
In conclusion, this study contributes to the characterization of
the genes of the apoptotic and survival pathways affected as a result
of the treatment of neuroblastoma cell cultures with 9-cis RA or
ATRA. Understanding these mechanisms is important because it
would help to understand neuronal development during embry-
onic stage and the relationship between the cell phenotype and/or
Retinoic Acid and Gene Expression in Neuroblastoma
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the RA isoform in the activation of a determined apoptosis
pathway.
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